|
| | | |
| Name | Alzheimer's | |
| Epidemiology | 5m US, 18m WW | |
| Etiology | Amyloid processing, Tau aggregation | |
| | Monomers, protofibrils, Fibrils - 10-100nm; Filament: 100A | |
| | | Thioflavin-T can be used to monitor fibril formation in vitro. |
| | AB histidine imidazole | |
| | AB40 | |
| | AB42 | |
| | AB*56 (Lesne et al). | |
| | primary nucleation, secondary fibril surface catalysed nucleation, elongation rate | |
| Chemistry | AB isoelectric point 5.3 (physiological reduction of pH, possibly due to inflammation, may result in AB insolubility) | |
| | pKa of three histidines is 6.7 | |
| Physiology | Cortex vs. hippocampus | |
| Genes/Proteins | TREM2, APP, alpha-secretase, beta-secretase, gamma-secretase, PSEN (presenilin) | |
| | APP | |
| | PSEN1 (presenilin-1) | |
| | PSEN2 (presenilin-2) - mutations cause AD | |
| | amyloid beta is produced from sequential processing of APP by BACE and gamma-secretase | |
| | amyloid beta sequence: isoaspartate at position 7 | |
| | Tottori FAD mutation (D678N) in APP | |
| | apoE, apoJ | |
| Scales | Adas-Cog, DAD, MMSE, NPI, CDR-SB, iADRS | |
| People | Dennis Selkoe | |
| Journals | Alzheimers Dement | |
| | Arch Neurol | |
| | J Neurosci | |
| | Alzheimers Res Treat | |
| | Nat Rev Neurology | |
| Companies | Eli Lilly | |
| | Biogen | |
| | Eisai | |
| | Merck | |
| | Roche | |
| | Sanofi | |
| | Abyssinia Biologics | |
| | Prothena | |
| | AbbVie | |
| | | |
| | Elan | |